What's the Outlook for Pfizer Stock?
As one of the world's largest pharmaceutical companies, Pfizer (NYSE: PFE) makes many of the most in-demand medications across the globe, netting more than $49 billion in trailing revenues in the process.
Pfizer is profitable, loaded with more than $11 billion in cash, and flush with new products on the horizon. But potential investors should be aware that Pfizer's stock hasn't beaten the market over the last decade, nor has it always performed favorably against its competitors. Further, many questions remain about the impact of the company's plan to sell Upjohn, its ailing generic medication manufacturing business.
Is Pfizer's stock due for a turn to faster growth, or should investors expect its weakness to continue? In my view, Pfizer's stock will benefit from the Upjohn sale because it will allow the company to shed an underperforming business unit. However, Pfizer will still need to bolster its collapsing earnings growth if it wants its stock to be a lucrative investment moving forward. Let's check out how Pfizer plans to deliver for its investors in the next year to see how realistic a return to growth might be.
Source Fool.com
